By Michael Doane IPPI Scholar & Assistant Professor of Law, The University of Akron School of Law Since the beginning, the second Trump Administration indicated that the promotion of domestic […]
Most-Favored-Nation (MFN) Drug Pricing: You Can’t Import European Prices Without Importing European Tradeoffs
By Dr. Gabriela Lenarczyk Dr. Lenarczyk is a 2024-2025 Edison Fellow. This blog post is in partial fulfillment of obligations for the Thomas Edison Innovation Law and Policy Fellowship. Recently resurfaced […]
The Problem With the ‘Patent Thicket’ Narrative
By Kristen Osenga Cross-posted with permission from Professor Osenga’s December 8, 2025, LinkedIn article I’ve seen a lot of misinformation circulating online lately about patents and their role in drug […]
TPLFA: Protecting Predatory Infringers
By Michael Doane The CEO of a small technology-based company with many groundbreaking patents in its field once asked me what the point was of obtaining patents when the company […]
IPPI Cautions that Pharmaceutical Tariffs Would Harm Patients and U.S. Innovation Leadership
IPPI has submitted formal comments to the U.S. Department of Commerce regarding its Section 232 investigation of pharmaceutical imports, cautioning against imposing tariffs on medicines and their ingredients. In our […]
RESTORE, PERA and PREVAIL: Bills that fix problems with the patent system
By Kristen Jakobsen Osenga As the 118th Congress drew to a close at the end of 2024, there was a spate of intellectual property activity on Capitol Hill. I was […]
[Archived Post] Panel on “SEP Current & Proposed Regulations” at C-IP2’s 2024 Annual Fall Conference
By Keith Mallinson It was my pleasure to participate in a panel session on “SEP Current & Proposed Regulations” last month at the George Mason University Antonin Scalia Law School […]
[Archived Post] Panelists at George Mason’s IP conference debate litigation funding
By Kristen Osenga I recently had the pleasure of participating in a panel on third-party litigation funding (TPLF), which was part of the Annual Fall Conference at George Mason University’s […]
[Archived Post] What the FTC Gets Wrong About the FDA’s Orange Book
By Emily Michiko Morris & Douglas Park The high cost of some pharmaceuticals is a complex issue, but the Federal Trade Commission’s (FTC’s) most recent criticism of pharmaceutical patents’ role […]
Pharmaceutical “Nominal Patent Life” Versus “Effective Patent Life,” Revisited
By Emily Michiko Morris and Joshua Kresh Executive summary: Many critics of pharmaceutical companies argue that they abuse the patent system through “evergreening” or “thickets” to increase the amount of […]